The use of CBD in the treatment of epilepsy is currently generating as much hope as it is questions. For several years, scientific studies and clinical trials have been investigating the potential of phytocannabinoids derived from hemp to reduce the frequency of seizures, particularly in certain rare and severe forms of epilepsy. Research is progressing rapidly, but all aspects of CBD’s efficacy, its potential side effects , and its place in treatment protocols for adults and children remain to be clarified. Let’s explore together the current state of medical knowledge on this sensitive topic.
Understanding Epilepsy and its Therapeutic Challenges Epilepsy encompasses a range of neurological disorders characterized by recurrent seizures due to abnormal electrical activity in the brain. While some patients respond well toconventional anti-epileptic drugs , nearly a third haverefractory epilepsy
, resistant to conventional treatments. This reality necessitates a constant search for new solutions to improve the quality of life for those affected. In children with syndromes such as Dravet or Lennox-Gastaut, the complexity of severe forms makes daily management particularly difficult. This context explains why the potential of CBD is attracting so much attention from both the scientific and advocacy communities involved in epilepsy. How does CBD affect epilepsy?Cannabidiol (CBD) is a non-psychoactive compound extracted from hemp. Unlike THC, it does not produce a high, but interacts with various receptors of the endocannabinoid system present in our bodies. According to current research, this interaction could help modulate neuronal activity and regulate the hyperexcitability responsible for epileptic seizures. Advances in The use of CBD for epileptic seizures demonstrates the strong interest in this compound as an alternative therapeutic approach, supported by analyses from various clinical studies. These studies also suggest that CBD influences different neurochemical circuits involved in the transmission of electrical signals.
Its exact role remains to be precisely defined, but interest in these mechanisms is growing as the results of clinical trials accumulate, particularly in children suffering from rare forms of epilepsy. What are the main hypotheses being investigated? The research explores several potential mechanisms of action ofcannabidiol:
Modulation of ion channels that participate in neuronal excitability Inhibition of pro-convulsant substancesin the brain Anti-inflammatory effect of CBD on brain tissue None of these avenues has been fully confirmed, but each contributes to a better understanding of the range of possibleneuroprotective properties of CBD
in the face of epilepsy. Which phytocannabinoids are being studied for epilepsy?
While CBD is the focus of most research, other molecules found in cannabis and hemp are also being studied. Among them, cannabidivarin (CBDV) seems to show promise, although its efficacy remains to be confirmed through further clinical trials.
- Currently, only cannabidiol has received genuine scientific validation in the field of epilepsy, while the literature on other phytocannabinoids is still emerging. Results of clinical studies on CBD and epilepsy
- The rise of CBD as a complementary treatment for epilepsy is based primarily on randomized clinical trials conducted in pediatric populations with rare syndromes. Results vary depending on the severity and nature of the disorder, as well as the individual profiles of the participants.
- A growing body of research highlights that
the beneficial potential of CBD on the frequency and intensity of epileptic seizures is of particular interest to families facing severe forms of the disease. In Dravet and Lennox-Gastaut syndromes
—two emblematic models of severe childhood epilepsy—several studies demonstrate a significant reduction in seizure frequency. Based on this data, cannabidiol is now authorized as an adjunct treatment in certain specific contexts. What are the observed success rates? Figures from clinical trials reveal significant variability in response: PopulationReduction rate ≥50%
Complete cessation of seizures Dravet syndrome 43 to 48% 5 to 7% Lennox-Gastaut syndrome
36 to 44%
3 to 6% These figures show that CBD offers significant improvement in some individuals, especially in cases of epilepsy resistant to multiple drug treatments. However, it is important to keep in mind that a significant proportion of patients do not experience major changes after the introduction of cannabidiol. Side effects and tolerability: what does the data say? Like any epilepsy treatment, CBD is not without side effects. Data extracted from studies point to some commonly reported side effects:
Drowsiness and decreased alertness Decreased appetite Diarrhea, mild nausea Transient elevation of liver enzymes The vast majority of observed events remain mild and reversible. However, specialized medical monitoring is necessary, particularly when combined with other anticonvulsants. Overall tolerability of CBD is considered satisfactory in the medium term.making its integration conceivable for certain categories of patients under strict supervision. Children, adults, and forms of epilepsy concerned In practice,
the documented benefits of CBD primarily concern children with rare and severe epilepsy,
including Dravet syndrome
| and Lennox-Gastaut syndrome. | For other types of epilepsy, the documentation remains sparse and often limited to | |
|---|---|---|
| preliminary or observational studies. | ||
| In adults, few controlled publications formally validate | the efficacy of CBD in the treatment of epilepsy. |
Access to cannabidiol outside the specific indications granted by health authorities must therefore remain exceptional and regulated.Can CBD be considered a universal solution against epilepsy? Currently,CBD appears more as a promising and complementary approach
rather than a general solution applicable to all epilepsy patients. This observation is shared by the majority of experts, urging the continuation of
clinical trials to broaden or refine the product’s indications.The positive impact observed in refractory epilepsyshould not overshadow the need for caution regarding more common forms, which still require significant scientific research before recommending CBD in all clinical situations.
- Legislation, Dispensing, and Medical Support
- The
- prescription of cannabidiol for medical useremains strictly regulated. In many European countries, only patients suffering from
- severe and debilitating forms
benefit from official authorization, via standardized products. There is therefore a major difference between the regulated use of pharmaceutical CBDand freely marketed wellness products.
Any trial of CBD in the treatment of epilepsyIt is imperative that treatment be coordinated by an experienced medical team. This allows for monitoring the occurrence of side effects, drug interactions, and fine-tuning of the protocol. Frequently Asked Questions about CBD and Epilepsy Can CBD replace traditional medications for treating epilepsy?CBD is generally not used as a complete substitute for traditional epilepsy medications. It is used as a complementary treatment for people with severe or refractory forms of epilepsy.Stopping or modifying conventional treatment should always be done in consultation with a specialized neurologist.
Dose adjustmentMonitoring of interactions Additional role only validated in certain syndromes What are the risks associated with CBD side effects in children?
The main side effects include drowsiness, fatigue, and even digestive problems. Regular liver monitoring is sometimes necessary, as elevated liver enzymes have been observed in some children. These effects necessitate close monitoring when initiating CBD treatment for pediatric epilepsy.
Increased fatigue, especially at the start of treatment; decreased appetite; possible interference with other therapies; side effects; frequency (%); drowsiness (20-30); decreased appetite (15-25). Are there differences in efficacy between adults and children? The majority of evidence of efficacy concerns children with severe or rare epilepsy. In adults, studies remain quite limited and results are less consistent. The lack of long-term data on use requires considerable caution in this age group. Robust evidence for Dravet and Lennox-Gastaut syndromes in children; insufficient data regarding adult epilepsy. Are all CBD products suitable for treating epilepsy?
No, only products extracted in a controlled manner and tested in clinical trials are suitable for the medical treatment of epilepsy. Oils or supplements sold over the counter do not guarantee the expected safety or effectiveness, and their quality varies greatly. It is recommended to follow only a protocol validated by a healthcare professional. Secure prescription
Standardized and analyzed product
Constant medical monitoring
